SpecGx

I've heard that as well, but only in my dreams.

At $46K/vial MNK would only need 1/2 the volume with the same paid rate than that of the past. Volume appears to be <50% of 2 years ago and the paid rate <50% of 2 years ago.

CVS, Tricare and Optum are bellwethers of the future if the strategy stays status quo. The payer situation is only getting worse, which happens when the price of an already expensive drug is doubled.

Insolvency could be the future with the debt load and declining revenue. There are 3 paths that MNK may take.

1. Stay on same course and end up insolvent.
2. Make a bold move with the payers, dropping the price and attempting to make up the difference in volume, and potentially end up insolvent.
3. Getting an indication like ALS, and then everything changes as Acthar becomes a multi billion $ product.

 

love these 2 people that clearly don’t either work at MNK or with Acthar. 1st off where the hell did 46k come from?!?! Not quite the price for a vial of Acthar genius. Second to the other post Acthar, Vial demand was up in Q2. ONLY vial demand THATS IT!!! If you know anything about this business and how to forecast the future you look and naive or “new referrals” and new prescribers along with adherence or “vials per patient” rates all those metrics were down slightly Q2 over Q1 18 and accelerated downward post 60 minutes, JAMA and CNN and have not fully recovered (less than half the decline has recovered) you then add to that the number of PAs expiring from Tricare and Optum patients who are no longer covered and whose PAs will not be extended and you also see declining adherence rates currently and accelerating over the next 90 days. All of which tells you despite what is likely to be a fairly decent Q2 earnings report next week that Q3 and Q4 are shaping up to be dismal!!!

As to an ALS indication that WILL NOT HAPPEN!!! You have a better chance of farting yourself to the moon than Acthar has at getting the ALS indication. That’s nothing more than a red herring management throws out to give people within the company and investors hope for the future. trust me when I say they are very scenical and calculating every time they tease that ALS possibility. These are dirty corrupt people at the top trying desperately to hang on to power.

It’s just a same because Acthar can change people’s lives. I’ve seen it dozens of times. We deserve better leadership and Acthar deserves a better owner.

 

“Acthar changing peoples lives”??? The only thing it changes is the patient now grows a pig’s tail after taking it.

 

sorry but it does. I won’t defend the company or it’s business practices but the drug works. Not for everyone but for sure there are patients that have tried every 1st, 2nd and 3rd line product with limited success whose, MS, Lupus, Vision etc has been controlled or saved by Acthar. That is a fact and anyone who has sold it has heard these stories from providers firsthand.

The MNK leadership sucks. But the drug can have a major impact people. It needs better leadership, more real studies vs retrospective BS and a fair and reasonable pricing strategy

 

Evidence based medicine ? If they wanted solid full proof clinical phase Iv data it would have been done by now . If you conduct one and it doesn’t work then you eliminate at TA = eliminate revenue = greedy bastards at mnk never will do that

 

just stop. You are ridiculous

 

It’s August 13. SpecGX is still part of Mallinckrodt. No further news is available about the alleged Aurobindo deal that was supposed to close in July. Looks like the rumors were false.

 

It looks like the deal will finally take place mid September. Take a look at the MNK stock price currently, it's about to double in the next month.

 

Sale not likely to go ahead.

 

If the sale falls through, then what will happen to SpecGX? Continuing the neglect of the division? Shutting down Generics and keeping API? Or a total shutdown?

 

It will be sold to Aurobindo. Time is EOY.

 

Mid September, EOY, whatever ¯\_(ツ)_/¯

 

Not with the FDA rejection today. Womp womp!

 

* KNOWN *

 

Good one, a .2% drop in stock prices after FDA ‘rejection’. Looks like you’re a wizard

 

Too many idiots got fired and go on here bitching about management.
It's good to see them not working at Mallinckrodt anymore.

 

The way things are going for Mallinckrodt, they had better keep generics just to pay the bills.

 

It will eventually be a write-off... no one is seriously interested in buying this piece of garbage